NASDAQ:CEMI - Chembio Diagnostics Stock Price, Price Target & More

Get Started

$8.75 -0.15 (-1.69 %)

(As of 05/24/2018 06:03 AM ET)

Previous Close$8.90

Today's Range$8.60 - $8.85

52-Week Range$5.70 - $9.20

Volume16,600 shs

Average Volume24,374 shs

Market Capitalization$126.05 million

P/E RatioN/A

Dividend YieldN/A

Beta1.21

About Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; and international diagnostics company to develop a POC diagnostic test for a specific type of cancer, as well as with AstraZeneca for the development of a POC assay for a novel biomarker. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CEMI

CUSIPN/A

Webwww.chembio.com

Phone631-924-1135

Debt

Debt-to-Equity RatioN/A

Current Ratio5.17

Quick Ratio3.86

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million

Price / Sales5.16

Cash FlowN/A

Price / CashN/A

Book Value$1.68 per share

Price / Book5.21

Profitability

EPS (Most Recent Fiscal Year)($0.52)

Net Income$-6,370,000.00

Net Margins-21.28%

Return on Equity-32.21%

Return on Assets-25.72%

Miscellaneous

Employees165

Outstanding Shares14,160,000

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics (NASDAQ:CEMI) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.09. The company earned $7.72 million during the quarter, compared to analyst estimates of $6.10 million. Chembio Diagnostics had a negative net margin of 21.28% and a negative return on equity of 32.21%. View Chembio Diagnostics' Earnings History.

Who are some of Chembio Diagnostics' key competitors?

Some companies that are related to Chembio Diagnostics include Zealand Pharma (ZEAL), Insys Therapeutics (INSY), Isotechnika Pharma (AUPH), Concert Pharmaceuticals (CNCE), ObsEva (OBSV), Cytokinetics (CYTK), Zymeworks (ZYME), Mersana Therapeutics (MRSN), Dermira (DERM), GTX (GTXI), Innate Pharma (IPHYF), Sinovac Biotech (SVA), Depomed (DEPO), Clearside Biomedical (CLSD) and ProMetic Life Sciences (PFSCF).

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:

Mr. John J. Sperzel III, B.Sc., CEO, Pres & Director (Age 54)
Mr. Neil A. Goldman, Exec. VP & CFO
Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
Ms. Sharon Klugewicz, Pres of Americas Region (Age 50)
Dr. Robert Passas Ph.D., Pres of EMEA & APAC Regions (Age 64)

Has Chembio Diagnostics been receiving favorable news coverage?

Headlines about CEMI stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chembio Diagnostics earned a coverage optimism score of 0.15 on Accern's scale. They also gave media coverage about the company an impact score of 47.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include Acuta Capital Partners LLC (14.17%), ARS Investment Partners LLC (6.07%), Cortina Asset Management LLC (3.70%), Gagnon Securities LLC (1.42%), Wells Fargo & Company MN (0.99%) and Gagnon Advisors LLC (0.92%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Neil A Goldman, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.

Which institutional investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC. View Insider Buying and Selling for Chembio Diagnostics.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Acuta Capital Partners LLC, Gagnon Securities LLC, Gagnon Advisors LLC, Wells Fargo & Company MN and Benchmark Capital Advisors. Company insiders that have bought Chembio Diagnostics stock in the last two years include Neil A Goldman and Norman H Pessin. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $8.75.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $126.05 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]

MarketBeat Community Rating for Chembio Diagnostics (CEMI)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		77 (Vote Outperform)
Underperform Votes:		84 (Vote Underperform)
Total Votes:		161

MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Chembio Diagnostics (NASDAQ:CEMI) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	N/A
Consensus Rating Score:	N/A	N/A	N/A	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Chembio Diagnostics (NASDAQ:CEMI) Consensus Price Target History

Price Target History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
11/11/2016	Benchmark	Set Price Target	Buy	$9.00	N/A

(Data available from 5/24/2016 forward)

Chembio Diagnostics (NASDAQ:CEMI) Earnings History and Estimates Chart

Earnings by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.10)	($0.10)	($0.10)
Q2 2018	1	($0.08)	($0.08)	($0.08)
Q3 2018	1	($0.08)	($0.08)	($0.08)
Q4 2018	1	($0.04)	($0.04)	($0.04)

Chembio Diagnostics (NASDAQ CEMI) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018	Q1 2018	($0.14)	($0.0490)	$6.10 million	$7.72 million	View	N/A
3/8/2018	Q4 2017	($0.10)	($0.16)	$5.66 million	$5.99 million	View	Listen
11/8/2017	Q3 2017	($0.11)	($0.05)	$5.65 million	$7.59 million	View	N/A
8/9/2017	Q2 2017	($0.1650)	($0.18)	$4.96 million	$2.89 million	View	Listen
5/9/2017	Q1 2017	($0.1950)	($0.1320)	$4.88 million	$5.43 million	View	Listen
3/7/2017	Q4 2016	($0.15)	($0.21)	$4.44 million	$4.26 million	View	Listen
11/10/2016	Q3 2016	($0.17)	($0.19)	$3.76 million	$3.75 million	View	N/A
8/11/2016	Q2	($0.11)	($0.86)	$6.72 million	$3.27 million	View	Listen
5/12/2016	Q1	($0.09)	($0.03)	$4.83 million	$6.60 million	View	Listen
3/8/2016	Q4	($0.09)	($0.07)	$6.56 million	$4.42 million	View	N/A
11/12/2015	Q3	($0.09)	($0.05)	$6.77 million	$6.89 million	View	Listen
8/6/2015	Q2	($0.03)	($0.07)	$7.53 million	$6.72 million	View	N/A
5/7/2015	Q115	($0.08)	($0.07)	$5.20 million	$6.20 million	View	N/A
3/5/2015	Q414	($0.04)	($0.05)	$7.10 million	$7.10 million	View	N/A
11/6/2014	Q3 2014	($0.03)	($0.03)	$7.71 million	$7.31 million	View	N/A
8/7/2014	Q2	($0.02)	($0.02)	$6.25 million	$7.42 million	View	N/A
5/8/2014	Q1 2014	($0.02)	($0.02)	$6.87 million	$5.81 million	View	N/A
3/6/2014	Q413	$0.04	($0.03)	$7.05 million	$7.86 million	View	N/A
11/7/2013	Q3 2013	$0.06	$0.07	$8.59 million	$9.62 million	View	N/A
8/8/2013	Q2 2013	($0.04)	($0.03)	$5.56 million	$5.39 million	View	N/A
5/9/2013	Q1 2013	$0.06	$0.04	$7.47 million	$6.31 million	View	N/A
3/7/2013	Q4 2012	$0.07	$0.06			View	N/A
11/13/2012	Q312	$0.04	($0.04)	$6.11 million	$5.01 million	View	N/A
8/9/2012		$0.05	$0.04			View	N/A
5/8/2012	Q1 2012	$0.08	$0.05			View	N/A
3/8/2012	Q4 2011	$0.08	$0.06			View	N/A
11/3/2011	Q3 2011		$0.06			View	N/A
8/4/2011	Q2 2011		$0.02			View	N/A
5/5/2011	Q1 2011		($0.02)			View	N/A
3/3/2011	Q4 2010		$0.22			View	N/A
11/4/2010	Q3 2010		$0.02			View	N/A
7/29/2010	Q2 2010	($0.08)	$0.07			View	N/A
5/6/2010	Q1 2010		($0.02)			View	N/A
3/5/2010	Q4 2009		$0.02			View	N/A
11/4/2009	Q3 2009		$0.03			View	N/A
5/8/2009	Q1 2009		($0.08)			View	N/A
11/12/2008	Q3 2008	($0.08)	($0.03)			View	N/A
8/4/2008	Q2 2008	($0.08)	($0.08)			View	N/A
3/13/2008	Q4 2007	($0.80)	($2.56)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Chembio Diagnostics (NASDAQ:CEMI) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Chembio Diagnostics (NASDAQ CEMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.65%
Institutional Ownership Percentage: 41.60%

Insider Trading History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ CEMI) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2018	Neil A Goldman	CFO	Buy	14,815	$6.75	$100,001.25	14,815
6/28/2017	Norman H Pessin	Insider	Buy	36,250	$5.48	$198,650.00
6/15/2016	Sharon W Klugewicz	COO	Sell	3,000	$8.40	$25,200.00	7,000
6/1/2016	Javan Esfandiari	Insider	Sell	25,000	$8.58	$214,500.00	79,110
5/29/2015	Javan Esfandiari	Insider	Sell	20,000	$4.50	$90,000.00
11/19/2014	Peter Kissinger	Director	Buy	1,800	$4.31	$7,758.00
2/26/2014	Sharon W Klugewicz	COO	Buy	10,000	$3.50	$35,000.00
12/6/2013	Javan Esfandiari	SVP	Sell	10,000	$3.40	$34,000.00
11/11/2013	Lawrence A Siebert	Major Shareholder	Sell	30,000	$3.63	$108,900.00

(Data available from 1/1/2013 forward)

Chembio Diagnostics (NASDAQ CEMI) News Headlines

Source:

Date	Headline
	Chembio Diagnostics and Massachusetts General Hospital Enter Memorandum Of Understanding to Develop Point-of-Care Fever Diagnostic Test finance.yahoo.com - May 22 at 9:25 AM
	Chembio Diagnostics Names John Potthoff, Ph.D. to its Board of Directors finance.yahoo.com - May 16 at 9:54 AM
	CEMI: Q1 2018: Product Sales Off To Strong Start, And Should Steepen From Here finance.yahoo.com - May 14 at 10:34 AM
	Chembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 12 at 10:22 AM
	Chembio Diagnostics (CEMI) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS www.americanbankingnews.com - May 11 at 5:41 PM
	Chembio Diagnostics beats by $0.09, beats on revenue seekingalpha.com - May 10 at 9:52 AM
	Edited Transcript of CEMI earnings conference call or presentation 9-May-18 8:30pm GMT finance.yahoo.com - May 10 at 9:52 AM
	Should You Buy Chembio Diagnostics Inc (NASDAQ:CEMI) At $7.95? finance.yahoo.com - May 9 at 4:21 PM
	Chembio Diagnostics Reports First Quarter 2018 Financial Results finance.yahoo.com - May 9 at 4:21 PM
	Chembio Diagnostics (CEMI) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - May 2 at 9:42 PM
	Wired News – Chembio Signs Collaboration Agreement with LumiraDx to Develop New Point-of-Care Diagnostic Tests finance.yahoo.com - April 27 at 10:13 AM
	Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018 finance.yahoo.com - April 26 at 4:19 PM
	Chembio teams up with LumiraDx to develop POC tests for infectious diseases seekingalpha.com - April 25 at 4:29 PM
	Chembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious Diseases globenewswire.com - April 25 at 9:48 AM
	Chembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious Diseases finance.yahoo.com - April 25 at 9:47 AM
	Chembio Diagnostics (CEMI) Upgraded to Sell at ValuEngine www.americanbankingnews.com - April 10 at 7:51 PM
	Chembio Diagnostics (CEMI) Lifted to "Buy" at ValuEngine www.americanbankingnews.com - April 3 at 5:52 PM
	Edited Transcript of CEMI earnings conference call or presentation 8-Mar-18 9:30pm GMT finance.yahoo.com - March 30 at 9:47 AM
	Q1 2018 Earnings Estimate for Chembio Diagnostics Inc Issued By Zacks Investment Research (CEMI) www.americanbankingnews.com - March 16 at 8:37 AM
	CEMI: Q4 2017: Strategic Successes and Recent Wins Sets Up 2018 To Be Another Strong Year finance.yahoo.com - March 14 at 10:44 AM
	Chembio Diagnostics (CEMI) Announces Earnings Results www.americanbankingnews.com - March 9 at 2:03 PM
	Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - March 8 at 5:06 PM
	Neil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) Stock www.americanbankingnews.com - February 13 at 3:18 PM
	Chembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/Sh www.streetinsider.com - February 10 at 8:57 AM
	Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results finance.yahoo.com - February 9 at 9:05 AM
	Chembio Diagnostics Announces Proposed Public Offering of Common Stock finance.yahoo.com - February 9 at 9:05 AM
	Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock finance.yahoo.com - February 9 at 9:05 AM
	ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017 finance.yahoo.com - December 28 at 3:57 PM
	Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 finance.yahoo.com - December 27 at 1:55 PM
	Chembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial Officer www.streetinsider.com - December 21 at 5:25 PM
	Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System finance.yahoo.com - December 21 at 9:23 AM
	Chembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial Officer finance.yahoo.com - December 20 at 9:25 AM
	Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test www.nasdaq.com - December 19 at 9:24 AM
	Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test finance.yahoo.com - December 19 at 9:24 AM
	Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.'s FY2018 Earnings (CEMI) www.americanbankingnews.com - December 11 at 10:50 AM
	CEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple Expansion finance.yahoo.com - December 7 at 5:53 PM
	Chembio Receives $4.2 Million in Accounts Receivable Payments from Bio-Manguinhos www.nasdaq.com - December 6 at 9:33 AM
	Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018 www.streetinsider.com - December 6 at 9:33 AM
	Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018 finance.yahoo.com - December 5 at 10:04 AM
	CEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 Growth finance.yahoo.com - November 20 at 6:13 PM
	Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT finance.yahoo.com - November 9 at 7:55 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017 finance.yahoo.com - November 9 at 7:55 PM
	CHEMBIO DIAGNOSTICS, INC. to Host Earnings Call finance.yahoo.com - November 8 at 8:42 PM
	Chembio Diagnostics Reports Third Quarter 2017 Financial Results finance.yahoo.com - November 8 at 8:42 PM
	Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017 finance.yahoo.com - November 7 at 8:03 PM
	Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results feeds.benzinga.com - November 1 at 9:28 AM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017 finance.yahoo.com - October 30 at 3:41 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017 finance.yahoo.com - October 17 at 5:50 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017 finance.yahoo.com - October 5 at 11:39 AM
	Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 finance.yahoo.com - October 4 at 12:24 PM

Chembio Diagnostics (NASDAQ:CEMI) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Chembio Diagnostics (NASDAQ:CEMI) Income Statement, Balance Sheet and Cash Flow Statement

Chembio Diagnostics (NASDAQ CEMI) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff